Study in France Shows Decrease in Severe COVID Cases with mRNA COVID-19 Vaccines and No Rise in Deaths

A comprehensive French study has provided strong evidence supporting the safety and effectiveness of mRNA COVID-19 vaccines, contradicting claims that they are harmful or linked to increased cancer risk. Conducted over nearly four years, the research monitored 22.7 million vaccinated people alongside 5.9 million unvaccinated individuals.

The findings reveal that those who received mRNA vaccines had a 74% lower chance of dying from severe COVID-19. Beyond that, vaccinated individuals showed a 25% lower risk of death from any cause, demonstrating broader health benefits.

Regarding cancer concerns, the study found that tumor rates were slightly lower among vaccinated adults769 per millioncompared to 853 per million in unvaccinated individuals. This indicates that vaccinated adults were roughly 15% less likely to develop cancer during the study period.

The researchers carefully adjusted for factors like healthier individuals being more likely to get vaccinated and the possibility that sicker individuals might avoid vaccination. Interestingly, those vaccinated in the study were generally older and had more chronic conditions such as obesity, which would normally increase mortality risk. The team suggests socioeconomic advantages among vaccinated participants may also play a role in the outcomes.

Lead author Mahmoud Zureik emphasized that the study provides clear data refuting misinformation about long-term risks of mRNA vaccines. "Providing data on the absence of long-term risks helps strengthen confidence in these vaccines, which will be developed for other viruses and diseases," Zureik stated.

These results reinforce the safety and protective benefits of mRNA COVID-19 vaccines and provide valuable evidence for public health decision-making.

Author: Logan Reeves